The International Consortium on Anti-Virals (ICAV)/ Consortium International sur les Thérapies Antivirales (CITAV) is led by Jeremy Carver, President and Chief Executive Officer. The Canadian ‘Not-For-profit’ drug development company was founded in 2004 to discover and develop novel anti-viral therapies for neglected and emerging diseases, and to ensure their global accessibility to all those in need.
ICAV recognizes the need for the international community to establish a capability to detect, contain and treat diseases and pandemics promptly in both the developed and developing worlds. ICAV supports the development of therapies for such viruses as Influenza, Dengue, HIV, Hepatitis, Lassa, Yellow Fever, Chikungunya, Ebola and Marburg, and other infectious viral diseases.
Visit the ICAV's website.
For more information about this initiative, please contact
Jeremy Carver, President